VEGFA and non-small cell lung carcinoma: E2 upregulates proangiogenic factors such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor BB (PDGF-BB) and promotes resistance to antiangiogenic therapies by enhancing tumor vascular pericyte coverage and myeloid recruitment in non-small cell lung cancer [9,10].